GMP, ISO custom synthesis Medicinal Chemistry; FDA new API and Intermediates, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided.
Teva, Novartis, Pfizer, Hikma, Glenmark, Gilead all Site Audit approved us.
www.eosmedchem.com
1.
Acalabrutinib , ACP-196, CAS# 1420477-60-6, HPLC 99.62%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 100g in stock
Name: Acalabrutinib (ACP-196)
CAS#: 1420477-60-6
Chemical Formula: C26H23N7O2
Exact Mass: 465.19132
Molecular Weight: 465.52
Elemental Analysis: C, 67.08; H, 4.98; N, 21.06; O, 6.87
Synonym: ACP-196; ACP196; ACP 196; Acalabrutinib
IUPAC/Chemical Name: (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
InChi Key: WDENQIQQYWYTPO-IBGZPJMESA-N
InChi Code: InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
SMILES Code: O=C(NC1=NC=CC=C1)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]5N(C(C#CC)=O)CCC5)=N3)C=C2
2.
Acalabrutinib Intermediates:
Acalabrutinib Intermediates, CAS# 1420478-88-1, (S)-benzyl 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
Acalabrutinib Intermediates, CAS# 1383385-64-5 , N-Pyridin-2-yl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl) -benzamide, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
,
Acalabrutinib Intermediates, CAS# 1420478-89-2, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
Acalabrutinib Intermediates, CAS#1420478-90-5, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
Acalabrutinib Intermediates, CAS#1418307-18-2, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
Acalabrutinib Intermediates, CAS#1418307-17-1, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
Acalabrutinib Intermediates, CAS#864759-39-7, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
Acalabrutinib Intermediates, CAS#850568-25-1, 4-(Pyridin-2-yl)aminocarbonylphenylboronicacid, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
Acalabrutinib Intermediates, CAS#939412-86-9, (3-Chloropyrazin-2-yl)MethanaMine hydrochloride, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
ADDITIONAL INFORMATION
Acalabrutinib is a potent and selective BTK (Bruton's tyrosine kinase) inhibitor. BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits signals from a variety of cell-surface molecules, including the B-cell receptor (BCR) and tissue homing receptors. Genetic BTK deletion causes B-cell immunodeficiency in humans and mice, making this kinase an attractive therapeutic target for B-cell disorders. BTK inhibitors targeting B cell receptor signaling and other survival mechanism showed great promise for the treatment of chronic lymphocytic leukemia (CLL)s holds great promise.
As of 2015 it is in late stage clinical trials for relapsed chronic lymphocytic leukemia. Interim results are encouraging : 95% overall response rate. It is also in another 20 clinical trials (alone and in combination) for various cancers.
REFERENCES
1: Maly J, Blachly JS. Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents. Curr Hematol Malig Rep. 2016 Feb 11. [Epub ahead of print] PubMed PMID: 26893063.
2: Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7. PubMed PMID: 26641137.
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
2018. 4.18 Janpan CPHI, Attend
2018. 5.15 Israel Biomed, Attend
2018. 6. 20 China CPHI, W4E82
2018. 8. 28 Korea CPHI, Attend
2018. 10. 9 Spain World CPHI, Attend
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
